News Report · Infectious Disease

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

June 11, 2026

Clinical Perspective

Ensitrelvir is indicated for adults and pediatric patients aged 12 years and older who have been exposed to COVID-19. The data supports a 70% reduction in symptomatic COVID-19 following exposure, providing a new tool for clinicians managing high-risk populations. How will this new option impact vaccination strategies and patient education regarding COVID-19 prevention?

Dr. Simran Kohli · Infectious Diseases

Ensitrelvir (Xocova) is approved for post-exposure prophylaxis of COVID-19 following contact with an infected individual, marking it as the first oral antiviral for this indication. This approval, granted by the FDA on May 29, 2026, is based on the SCORPIO-PEP trial, which demonstrated significant efficacy in preventing COVID-19 infection in high-risk individuals ^[4].

Clinical Context

COVID-19, caused by the SARS-CoV-2 virus, continues to pose a significant public health challenge, particularly for individuals at high risk of severe disease. Current treatments primarily focus on managing active infections rather than preventing them post-exposure. While vaccines have been effective in reducing the incidence of severe COVID-19, there remains a need for effective post-exposure prophylaxis, especially in vulnerable populations. The approval of Ensitrelvir addresses this gap by providing an oral antiviral option for individuals who have been exposed to the virus, potentially reducing the risk of developing COVID-19 after exposure.

Key Findings

The SCORPIO-PEP trial showed Ensitrelvir achieved a 70% reduction in the risk of symptomatic COVID-19 following exposure compared to placebo ^[4].
The trial enrolled 1,200 participants who were at high risk of COVID-19 infection due to exposure to confirmed cases ^[4].
Event rates: 5% of participants receiving Ensitrelvir developed symptomatic COVID-19 compared to 17% in the placebo group ^[4].
The primary endpoint was the incidence of symptomatic COVID-19 through 14 days post-exposure ^[4].
Secondary analyses indicated that Ensitrelvir was effective across various demographics, including older adults and those with comorbidities ^[4].
Ensitrelvir is administered at a dose of 100 mg orally once daily for five days ^[4]. Clinicians should consult current prescribing information for full dosing guidance.

Safety & Tolerability

Nausea reported with Ensitrelvir — exact frequency not available in public source summary ^[4].
Diarrhea reported — exact frequency not available in public source summary ^[4].
Fatigue reported ^[4].
Liver enzyme elevations — advise monitoring during treatment ^[4].
Hypersensitivity reactions reported ^[4].
Complete adverse event profile available in the full prescribing information for Ensitrelvir (Xocova).

Study Design

The SCORPIO-PEP trial was a multicenter, randomized, double-blind, placebo-controlled study involving 1,200 participants who had close contact with individuals confirmed to have COVID-19. The primary endpoint was the incidence of symptomatic COVID-19 within 14 days of exposure, with a follow-up period to assess safety and tolerability. The trial was funded by the manufacturer, with key limitations including a focus on high-risk populations and the need for further studies to evaluate long-term efficacy and safety.

FAQ

What is Ensitrelvir (Xocova) approved for?

Ensitrelvir is approved for post-exposure prophylaxis of COVID-19 following contact with an individual who has COVID-19 as of May 29, 2026.

How does Ensitrelvir work?

Ensitrelvir is an oral antiviral that inhibits the replication of the SARS-CoV-2 virus, thereby preventing the onset of symptomatic COVID-19 following exposure.

What is the recommended dose of Ensitrelvir?

The recommended dose of Ensitrelvir is 100 mg taken orally once daily for five days. Clinicians should consult current prescribing information for full dosing guidance. Full dosing guidance is available in the prescribing information for Ensitrelvir (Xocova).

What are the most common side effects of Ensitrelvir?

Common side effects include nausea, diarrhea, fatigue, and potential liver enzyme elevations. Monitoring is advised during treatment.

How does Ensitrelvir compare to other COVID-19 treatments?

Ensitrelvir is the first oral antiviral approved specifically for post-exposure prophylaxis of COVID-19, distinguishing it from other treatments that are primarily for active infections.

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

FDA Approves Ensitrelvir for COVID-19 Post-Exposure Prevention: First Oral Antiviral in 2026

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly drug updates for Infectious Disease in your inbox.

Related Drug Updates

FDA Approves Rezafungin for Invasive Candidiasis: 70.2% Efficacy in ReSTORE Trial

CDC Updates Childhood Immunization Schedule: HPV, COVID, and Influenza Recommendations Reverted

FDA Approves Zoliflodacin for Gonorrhea: Novel Mechanism and Resistance Profile

Verified HCP Portal